Your browser doesn't support javascript.
loading
Comparison of Efficacy between Pemafibrate and Omega-3-Acid Ethyl Ester in the Liver: the PORTRAIT Study.
Sumida, Yoshio; Toyoda, Hidenori; Yasuda, Satoshi; Kimoto, Satoshi; Sakamoto, Kazumasa; Nakade, Yukiomi; Ito, Kiyoaki; Osonoi, Takeshi; Yoneda, Masashi.
Afiliação
  • Sumida Y; Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University.
  • Toyoda H; Department of Gastroenterology, Ogaki Municipal Hospital.
  • Yasuda S; Department of Gastroenterology, Ogaki Municipal Hospital.
  • Kimoto S; Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University.
  • Sakamoto K; Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University.
  • Nakade Y; Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University.
  • Ito K; Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University.
  • Osonoi T; Nakakinen Clinic.
  • Yoneda M; Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University.
J Atheroscler Thromb ; 2024 May 21.
Article em En | MEDLINE | ID: mdl-38777770
ABSTRACT

AIM:

No pharmacotherapeutic treatment has been established for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). This trial compared the effects of pemafibrate and omega-3-acid ethyl ester on hepatic function in patients with hypertriglyceridemia complicated by MASLD.

METHODS:

Patients with hypertriglyceridemia complicated by MASLD were enrolled, randomly assigned to the pemafibrate or omega-3-acid ethyl ester group, and followed for 24 weeks. The primary endpoint was the change in alanine aminotransferase (ALT) from baseline to week 24. The secondary endpoints included other hepatic enzymes, lipid profiles, and hepatic fibrosis biomarkers.

RESULTS:

A total of 80 patients were enrolled and randomized. The adjusted mean change in ALT from baseline to week 24 was significantly lower in the pemafibrate group (-19.7±5.9 U/L) than in the omega-3-acid ethyl ester group (6.8±5.5 U/L) (intergroup difference, -26.5 U/L; 95% confidence interval, -42.3 to -10.7 U/L; p=0.001). Pemafibrate significantly improved the levels of other hepatic enzymes (aspartate aminotransferase and gamma-glutamyl transpeptidase), lipid profiles (triglycerides, total cholesterol, high-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol), and hepatic fibrosis biomarkers (Mac-2 binding protein glycan isomer and Fibrosis-4 index). No cases of discontinuation due to adverse drug reactions were identified in either group, and there were no safety concerns.

CONCLUSIONS:

Pemafibrate is recommended over omega-3-acid ethyl ester for lipid management and MASLD treatment in patients with hypertriglyceridemia complicated by MASLD. The study results may contribute to the development of future treatment strategies for patients with MASLD/MASH.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article